Effect of Aidi injection combined with oxaliplatin and docetaxel in treatment of advanced non-small cell lung cancer

TANG Yu; SHI Lin

doi:10.3969/j.issn.1671-6450.2014.05.001

Abstract：Objective To explore the short and long term efficacy and clinical safety of Aidi injection combined with oxaliplatin (L-OHP) and docetaxel (DXL) in treatment of advanced non-small cell lung cancer (NSCLC).Methods Selected 91 patients from September 2009 to August 2010 with NSCLC, they were randomly divided into single-blind observation group (47 cases) and control group (44 cases).The control group using L-OHP +DXL 4 cycles of chemotherapy, observation group added Aidi intravenous injection , 50 ml/d, in 14 d, same cycles as control group , three months after the end of chemo-therapy , two groups were compared the efficacy and quality of life , 36 months after the therapy , long-term survival comparison were performed between the two groups .Results (1) 3 months after the end of chemotherapy , the observation group and the control group patients'overall response rate was 72.3%and 52.3%, respectively, KPS quality of life score was (81.4 ±5.4) points, and (78.7 ±5.7) points, respectively, the differences were statistically significant ( P <0.05).(2) The observa-tion group and the control group during chemotherapy overall incidence of toxicities are as follows , gastrointestinal reactions , neutropenia, thrombocytopenia, peripheral neurotoxicity, liver damage, kidney damage, skin rash, two groups'toxicity level constitute revealed no significant difference ( P >0.05).(3) 36 months after the end of chemotherapy , in the observation group and the control group , the average survival time was 31.030 (95%CI 30.752-31.308) months, 28.884 (95% CI 28.609-29.459) months, the cumulative probability of survival was (0.232 ±0.011), (0.088 ±0.008), showed a statis-tically significant difference ( P <0.01).Conclusion Aidi injection combined with L-OHP+DXL regimen in treatment of advanced NSCLC could significantly improve the recent efficiency , prolong survival duration after chemotherapy , and show good clinical safety .